Results 191 to 200 of about 1,505,630 (287)

Integrated spherical nucleic acid nanoreactor mobilizes targeted PD‐L1 proteolysis and cuproptosis for robust breast cancer immunotherapy

BMEMat, EarlyView.
This study provides an integrated spherical nucleic acid nanoreactor (denoted as AMCuD) for targeted PD‐L1 degradation and chemo‐dynamically enhanced cuproptosis to synergically elicit robust immunotherapy against the triple‐negative breast cancer (TNBC) growth, recurrence and metastasis.
Ningxi Li, Honglin Huang, Qianyi Zeng, Li Zeng, Ziman Yang, Jinyang Shen, Shun Li, Hong Yang, Yiyao Liu, Chunhui Wu   +9 more
wiley   +1 more source

CD47 monoclonal antibody enhances the inhibitory effect of anti-HER2 chimeric antigen receptor macrophages on ovarian cancer. [PDF]

Oncol Lett
Qiao J, Kou Q, Qiu J.
europepmc   +1 more source

Tackling cancer stemness with nanotechnology in the era of precision medicine

BMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo, Shun Yao, Lihui Meng, Chunyuan Chen, Yuechu Lucinda Lu, Rong Lu, Kashif Rafiq Zahid, Umar Raza, Qingzhi Wu, Wenli Chen   +9 more
wiley   +1 more source

Chimeric antigen receptor T‑cell therapy in chronic viral infections: a review. [PDF]

J Transl Med
Han Q, Zhang X, Chen L, Zhang Y.
europepmc   +1 more source

From pathogen to “living drug factory” innovative strategies and clinical translation of bacteria as programmable intelligent vectors for cancer therapy

BMEMat, EarlyView.
Engineered bacteria serve as smart, living therapeutics that target tumors, deliver drugs, and remodel immunosuppressive microenvironments. This review highlights their potential to potentiate immunotherapy, radiotherapy, and chemotherapy, offering a promising paradigm for precise and synergistic cancer treatment. Abstract The dynamic interplay between
Haonan Shen, Weichen Zhang, Gaoli Niu, Li Wang, Ruiyan Li, Yueyue Fan, Feixue Lu, Lingling Xu, Xiaoyuan Ji, Yong Kang   +9 more
wiley   +1 more source

IFNγ-induced antigen loss in chimeric antigen receptor-T cell therapy. [PDF]

Front Immunol
Cao M, Alvarez J, Mitra R, Xu M, Baybutt TR, Sun Z, Taylor O, Doermann AS, Staudt RE, Waldman SA, Snook AE.   +10 more
europepmc   +1 more source

Status and future of recombinant adeno‐associated virus vector manufacturing

Biotechnology Progress, EarlyView.
Abstract Sixty years of adeno‐associated virus (AAV) research illustrates a trajectory marked by basic science exploration, iterative innovation, persistent challenges, a number of clinical setbacks, as well as commercial therapeutic triumphs. This continual evolution has led to recombinant AAV (rAAV) becoming a cornerstone of modern gene therapy ...
Frank Agbogbo, David Dismuke
wiley   +1 more source

Prospects of Chimeric Antigen Receptor T-Cell Therapy in Myelofibrosis: From Immunopathogenesis to Therapeutic Strategies. [PDF]

Cancers (Basel)
Kong L, Fu C, Song L, Wang W, Ji M, Li F, Shi X, Chen W.   +7 more
europepmc   +1 more source

From Caffeine to Aspirin: Everyday Molecules as Triggers for Genetically Encoded Proximity Systems

Chemistry – A European Journal, EarlyView.
This Perspective article highlights how familiar dietary ingredients and over‐the‐counter (OTC) drugs (such as caffeine and its metabolites, SA, and aspirin) can be repurposed as clinically translatable chemical triggers for genetically encoded proximity systems.
Mingguang Cui, Tianlu Wang, Yaoyu Han, Yun Huang, Tien‐Hung Lan, Yunbin Zhou   +5 more
wiley   +1 more source

Fate induction through asymmetric T cell division is modulated by chimeric antigen receptor costimulatory domains. [PDF]

Nat Immunol
Frazee CS, Chen S, Berry CT, Lee CS, Banciella RA, Ngo L, Shon D, Herman PJ, Fischman JS, Leff CL, Chen A, Kuo Y, Shestov AA, Kelly AR, Valentic B, Milone MC, O'Connor RS, Ellebrecht CT.   +17 more
europepmc   +1 more source